| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790749 | American Journal of Ophthalmology | 2018 | 8 Pages |
Abstract
Although an overall cost-benefit ratio of government-sponsored research is difficult to estimate because the benefit may be diffuse and delayed, the investment in OCT over 2 decades has been recouped many times over in just a few years through better personalized therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Matthew A. Windsor, Sissi J.J. Sun, Kevin D. Frick, Eric A. Swanson, Philip J. Rosenfeld, David Huang,